Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

3. Astellas pays $50M for option on AviadoBio's dementia gene therapy Continuing its investments in cell and gene therapy, ...

The Japanese big pharma adds the new gene therapy candidate to its pipeline in a US$50 million deal in equity and upfront ...

AlphaFold’s developers were awarded science’s top prize. Elsewhere, J&J is shuttering an intriguing cancer study and Alnylam ...

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand ...

Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...

Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma Inc. Astellas is making a $20 ...

UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license ...

Astellas will make a $20 million equity investment in AviadoBio for the option to exclusively develop and commercialize AVB-1010.

The agreement leverages King's College London spin-out company's expertise in developing targeted gene therapy for ...

AviadoBio and Astellas Pharma announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene ...